Clinical Trial Update: SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating SHR-A1921 for injection in patients with platinum-resistant recurrent epithelial ovarian cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• SHR-A1921

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Ovarian Cancer | Phase 3 | Status: RECRUITING